Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -244,178 | -153,071 | -126,496 | -60,921 | -153,645 |
| Depreciation Amortization | 7,492 | 5,244 | 3,147 | 1,472 | 1,039 |
| Accounts receivable | -2,102 | 7 | 7 | 2 | 215 |
| Accounts payable and accrued liabilities | 8,434 | 3,999 | 24,155 | -8,319 | 9,757 |
| Other Working Capital | 4,558 | 2,513 | 21,744 | -17,281 | 2,015 |
| Other Operating Activity | 28,748 | 418 | 2,411 | 15,921 | -23,307 |
| Operating Cash Flow | $-197,048 | $-140,890 | $-75,033 | $-69,126 | $-163,925 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -5,778 | -4,481 | -3,125 | -2,804 | -3,127 |
| Investing Cash Flow | $-5,778 | $-4,481 | $-3,125 | $-2,804 | $-3,127 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 592,852 | 582,714 | 585,797 | 581,479 | 255,551 |
| Other Financing Activity | -40,028 | -38,579 | -38,177 | -37,355 | -15,492 |
| Financing Cash Flow | $552,824 | $544,135 | $547,621 | $544,123 | $240,058 |
| Exchange Rate Effect | 8,676 | 24,684 | -5,821 | 3,482 | 24,440 |
| Beginning Cash Position | 311,205 | 308,983 | 312,317 | 315,596 | 230,710 |
| End Cash Position | 669,879 | 732,430 | 775,959 | 791,271 | 328,155 |
| Net Cash Flow | $358,673 | $423,447 | $463,642 | $475,675 | $97,446 |
| Free Cash Flow | |||||
| Operating Cash Flow | -197,048 | -140,890 | -75,033 | -69,126 | -163,925 |
| Capital Expenditure | -5,778 | -4,481 | -3,125 | -2,804 | -3,127 |
| Free Cash Flow | -202,826 | -145,372 | -78,157 | -71,930 | -167,053 |